A5102770313- Prostate Cancer Treatment and Research
- Hippo pathway signaling and YAP/TAZ
- Biotechnology and Related Fields
- Ubiquitin and proteasome pathways
- Monoclonal and Polyclonal Antibodies Research
- Genomics and Chromatin Dynamics
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- HER2/EGFR in Cancer Research
- Estrogen and related hormone effects
- Biomedical and Engineering Education
The University of Adelaide
2016-2017
Freemasons Foundation Centre for Men's Health
2016-2017
International Iberian Nanotechnology Laboratory
2014-2015
Abstract Alteration to the expression and activity of androgen receptor (AR) coregulators in prostate cancer is an important mechanism driving disease progression therapy resistance. Using a novel proteomic technique, we identified new AR coregulator, transcription factor Grainyhead-like 2 (GRHL2), demonstrated its essential role oncogenic signaling axis. GRHL2 colocalized with tumors was frequently amplified upregulated cancer. Importantly, maintained multiple model systems, required for...
The epidermal growth factor receptor (EGFR) is a member of the ErbB family tyrosine kinases. EGFR activated upon binding to e.g. (EGF), leading cell survival, proliferation and migration. overactivation associated with tumor progression. We have previously shown that low dose UVB illumination cancer cells overexpressing prior adding EGF halted signaling pathway. here show extracellular domain (sEGFR) induces protein conformational changes, disulphide bridge breakage formation tryptophan...